The global non-invasive prenatal testing market is expected to

BRUSSELS, Belgium, May 10, 2022 (GLOBE NEWSWIRE) —

The description:

The non-invasive prenatal test (NIPT) is a method to determine the risk of the mother’s fetus being born with certain genetic abnormalities. NIPT is a safe and highly effective means of screening for conditions such as Down’s Syndrome, Edwards’ Syndrome, Patau’s Syndrome, Monosomy X, and Turner’s Syndrome.

Currently, there are two types of NIPT methods that are commercially available, massive parallel sequencing (MPS) technology and single nucleotide polymorphism (SNP) based method.

Change toward VSell-free DNA screening

The discovery of cell-free DNA (cfDNA)-based NIPT has created a rapid shift in the paradigm of aneuploidy screening in pregnancy. This is a simple blood test that can be done during pregnancy. Clinical validation studies suggest that NIPT is more accurate than combined first trimester screening (CFTS), with very high sensitivity (99.3%) and specificity (99.9%) for trisomy 21 (trisomy 21 syndrome). Down). NIPT is also safer than other invasive diagnostic techniques such as chorionic villus sampling and amniocentesis, which carries a risk of miscarriage (0.1-0.2%).

Advent of the advanced Technologies for NIPT products

The advent of next-generation sequencing technology has enabled the sequencing of fetal DNA fragments that can be assembled into a complete genetic map, allowing the fetal genome to be scanned prenatally and non-invasively. Developments in molecular technologies and the discovery of cell-free fetal DNA in maternal plasma have also led to new methods of screening for fetal chromosomal aneuploidies.

Currently, various types of NIPT tests are available in the market such as Panorama, Vistara, MaterniT GENOME, Harmony Test, among others, which help in the detection of chromosomal abnormalities developing in the fetus. In addition, several changes have been made to impact the quality of care for pregnant women, such as:

  • In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to the QIAGEN dPCR franchise.
  • In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of VeriSeq NIPT Solution v2 based on next-generation sequencing (NGS) in the country, which helps detect abnormalities missed by targeted testing.

Prenatal care is a dynamic and ever-changing field. Development in new molecular technologies and the discovery of cell-free fetal DNA fuel revolutionary advances improving maternal and child care and providing parents with reproductive options. Main directortor, Head of Product Research and Development, Sequencing and array-based Company, United States

Main challenges/constraints: Non-Invasive Prenatal Testing Market

Some of the major challenges limiting the growth of the non-invasive prenatal test market are stringent government regulations and limitations of NIPT such that despite its high accuracy, it is still considered a screening test.

North America: Largest NIPT market

North America is the largest market for NIPT with over 45% revenue share, followed by Europe. The increasing prevalence of genetic disorders in newborns coupled with increasing maternal age, wider adoption and the presence of leading players working on fetal and neonatal care in this region are some of the one of the main factors driving the North American market.

The NIPT market in Europe is expected to grow significantly over the forecast period owing to the adoption of latest technologies, new product launches and a strong reimbursement framework for such tests in the region. The Asia-Pacific region is expected to witness the highest CAGR in the coming years.

Competitive landscape Analysis: Non-Invasive Prenatal Testing Market

Some of the major players operating in the global non-invasive prenatal testing market are Agilent Technologies, BGI Genomics, Cradle Genomics, Berry Genomics, Sequenom, Roche (Ariosa Diagnostics), among others.

Explore detailed information about Global Non-invasive prenatal screening (NIPT) Market @

About Medi-Tech Insights:

Medi-Tech Insights is a business research and analytics company focused on healthcare. Our clients include Fortune 500 companies, blue chip investors and hyper-growth start-ups. We have successfully completed more than 100 projects in digital health, health informatics, medical technology, medical devices and pharmaceutical services.

Contact We:

Ruta Halde
Partner, Medi-Tech Insights
+32 498 86 80 79
[email protected]

Comments are closed.